Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético

Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab. Aim: To assess the outcomes of patients with MCL treated in a univ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Campbell,James, Hurtado,Sebastián, Kutz,Consuelo, Soto,Katherine, Ernst,Daniel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Lymphoma Mantle-Cell Cytarabine Hematopoietic Stem Cell Transplantation Rituximab Chile
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000100009
record_format	dspace
spelling	oai:scielo:S0034-988720190001000092019-04-03Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyéticoCampbell,JamesHurtado,SebastiánKutz,ConsueloSoto,KatherineErnst,Daniel Lymphoma Mantle-Cell Cytarabine Hematopoietic Stem Cell Transplantation Rituximab Chile Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and Methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with rituximab or HCT was associated with better PFS (48 vs 21 months, p < 0.01). The exposure to AraC or HCT, in refractory or relapsed disease, was associated with an increase in PFS from 9 to 28 months (p = 0,02) and 4-year OS from 40 to 100% (p = 0.05). OS increased even more, from 25 to 100% in those with high-risk MIPI (p = 0.04). Conclusions: The incorporation of AraC, HCT and maintenance with rituximab in the therapeutic backbone of MCL, especially for high-risk cases, was associated with improved survival.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.1 20192019-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100009es10.4067/S0034-98872019000100009
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Lymphoma Mantle-Cell Cytarabine Hematopoietic Stem Cell Transplantation Rituximab Chile
spellingShingle	Lymphoma Mantle-Cell Cytarabine Hematopoietic Stem Cell Transplantation Rituximab Chile Campbell,James Hurtado,Sebastián Kutz,Consuelo Soto,Katherine Ernst,Daniel Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
description	Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and Methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with rituximab or HCT was associated with better PFS (48 vs 21 months, p < 0.01). The exposure to AraC or HCT, in refractory or relapsed disease, was associated with an increase in PFS from 9 to 28 months (p = 0,02) and 4-year OS from 40 to 100% (p = 0.05). OS increased even more, from 25 to 100% in those with high-risk MIPI (p = 0.04). Conclusions: The incorporation of AraC, HCT and maintenance with rituximab in the therapeutic backbone of MCL, especially for high-risk cases, was associated with improved survival.
author	Campbell,James Hurtado,Sebastián Kutz,Consuelo Soto,Katherine Ernst,Daniel
author_facet	Campbell,James Hurtado,Sebastián Kutz,Consuelo Soto,Katherine Ernst,Daniel
author_sort	Campbell,James
title	Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
title_short	Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
title_full	Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
title_fullStr	Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
title_full_unstemmed	Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
title_sort	resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100009
work_keys_str_mv	AT campbelljames resultadosdepacientesconlinfomadelmantoimpactodeterapiasbasadasencitarabinaytrasplantehematopoyetico AT hurtadosebastian resultadosdepacientesconlinfomadelmantoimpactodeterapiasbasadasencitarabinaytrasplantehematopoyetico AT kutzconsuelo resultadosdepacientesconlinfomadelmantoimpactodeterapiasbasadasencitarabinaytrasplantehematopoyetico AT sotokatherine resultadosdepacientesconlinfomadelmantoimpactodeterapiasbasadasencitarabinaytrasplantehematopoyetico AT ernstdaniel resultadosdepacientesconlinfomadelmantoimpactodeterapiasbasadasencitarabinaytrasplantehematopoyetico
_version_	1718437041240276992

Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético

Ejemplares similares